Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€26.98

€26.98

1.850%
0.49
1.850%
-
 
18:21 / Tradegate WKN: 578560 / Symbol: FSNUF / Name: Fresenius / Stock / Healthcare Providers & Services / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Description Fresenius

Fresenius SE Co. KGaA is a healthcare company based in Germany that operates in various segments including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed.

Fresenius Medical Care is a global leader in the production of dialysis products and services. Fresenius Kabi is responsible for manufacturing and distributing pharmaceutical products such as infusion therapies, clinical nutrition, and anaesthetics. Fresenius Helios operates a network of hospitals and outpatient centres across Germany, and Fresenius Vamed is engaged in the management and construction of healthcare facilities.

Fresenius has a market capitalization of approximately €31 billion euros and is listed on the Frankfurt Stock Exchange under the symbol FME. The company is also listed on the United States OTC market under the symbol FSNUF. The company is known for its commitment to high quality standards, innovation, and clinical excellence in healthcare.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Fresenius SE & Co. KGaA is only available for our menbers.
Not a member yet? Sign up for free!

Competitors of Fresenius

Fresenius SE Co. KGaA (FSNUF) is a German multinational healthcare company that specializes in the production of medical devices, pharmaceutical products, and services. As a result, its competitors may vary depending on the segment of the business being considered.

Here are some of the most important competitors of Fresenius in its various areas of operation:

1. Medical Devices: Key competitors in this segment include Johnson Johnson, Medtronic Plc, Stryker Corporation, and Becton, Dickinson and Company.

2. Pharmaceutical Products: Major competitors in this segment include Pfizer Inc., Roche Holding AG, GlaxoSmithKline plc, and Sanofi SA.

3. Services: Competitors in this segment include DaVita Inc., UnitedHealth Group Inc., CVS Health Corporation and Express Scripts Holding Company.

It is also worth noting that Fresenius operates globally and may face different competitors in different regions, depending on regulatory regimes, product demand, and other factors. Additionally, there may be local competitors depending on the specific market, geography and area of operation.

Financial data and news for Fresenius

sharewise wants to provide you with the best news and tools for Fresenius, so we directly link to the best financial data sources.

News

EQS-AGM: Fresenius SE & Co. KGaA: Announcement  of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023